What is the main purpose of this 8-K filing?

This 8-K filing primarily announces executive compensation actions and equity grants for 2007, as well as the formalization of an employment agreement for David C. Colby, who also received the additional title of Vice Chairman.

What types of equity awards were granted to executives?

Executives received stock option grants and restricted stock unit (RSU) awards. The stock options have a vesting schedule over three years, and the RSUs have vesting contingent on achieving specific performance targets, primarily related to adjusted diluted Earnings Per Share (EPS).

How is the annual bonus for executives determined?

The annual bonus for 2007 is based on a performance matrix with a significant weighting towards adjusted diluted EPS (40%). Other performance measures include Business Unit Operating Gain, Specialty Performance, Medical Membership Growth, Member Health Index, and Member Trust. A minimum adjusted diluted EPS threshold must be met for any bonus to be paid.

What was the exercise price for the stock options granted?

The exercise price for the stock options granted on March 1, 2007, was equal to the fair market value based on the closing market value of WellPoint’s Common Stock on the New York Stock Exchange on that date, which was $80.81 per share.

ELV 8-K: Leadership Changes

Summary

This Form 8-K filing by WellPoint, Inc. (now Elevance Health, Inc.) on March 5, 2007, primarily details significant changes in executive compensation and roles. Notably, it announces the formalization of David C. Colby's employment agreement as Executive Vice President, Chief Financial Officer, and Vice Chairman, along with substantial equity grants including stock options and restricted stock units. The filing also outlines the 2007 compensation packages for other key executive officers, including base salaries, stock option grants, restricted stock unit awards, and annual bonus targets, highlighting the performance-based nature of these incentives. Investors should pay close attention to the details of these equity grants and the performance metrics tied to restricted stock unit vesting and annual bonuses. The emphasis on adjusted diluted Earnings Per Share (EPS) as a key performance indicator for both bonuses and equity awards signals the company's strategic focus on profitability and growth. The structure suggests an alignment of executive interests with shareholder value creation, with significant portions of compensation contingent on achieving specific financial and operational targets.

Key Highlights

1Formalization of David C. Colby's employment agreement as EVP, CFO, and Vice Chairman.
2David C. Colby received a stock option grant for 40,000 shares and a restricted stock unit award for 20,000 shares, both vesting over two years.
3Executive compensation for 2007 was detailed, including base salaries, stock option grants, restricted stock unit awards, and annual bonus targets for key officers.
4Stock option grants for 2007 were made at the closing market value of $80.81 per share on March 1, 2007.
5Restricted stock unit awards for 2007 have vesting contingent on achieving specified adjusted diluted Earnings Per Share (EPS) thresholds for 2007.
6Annual bonuses for 2007 are tied to a performance matrix including adjusted diluted EPS (40%), Business Unit Operating Gain (20%), Specialty Performance (15%), Medical Membership Growth (15%), Member Health Index (5%), and Member Trust (5%).
7A threshold adjusted diluted EPS must be met for any 2007 Annual Incentive Bonus to be paid.

Elevance Health, Inc. 8-K Report, Executive Changes (Mar 5, 2007)

Summary

Key Highlights

Frequently Asked Questions